MedTrace Logo

Repeat Ivermectin Mass Drug Administrations for MALaria Control II

NCT03967054 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 4124

Last updated 2025-04-10

Study results available
· View outcomes & findings →

Summary

RIMDAMAL II is a double-blind, cluster randomized trial in Burkina Faso designed to test whether repeated ivermectin mass drug administrations, integrated into a monthly delivery platform with standard malaria control measures of seasonal malaria chemoprevention and insecticide-treated bed net distribution in the Sahel, will reduce childhood malaria incidence.

Conditions

Interventions

DRUG

Ivermectin

Ivermectin (6 mg tablet) given monthly from July-October each rainy season as a 3-day course of approximately 300 mcg/kg/day as estimated by height bands.

DRUG

Placebo oral tablet

placebo in the same size, color and shape at the ivermectin tablet

Sponsors & Collaborators

  • Yale University

    collaborator OTHER

  • Institut de Recherche en Sciences de la Sante-Direction Regionale de l'Ouest

    collaborator OTHER_GOV

  • Radboud University Medical Center

    collaborator OTHER

  • PATH

    collaborator OTHER

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Brian Foy

    lead OTHER

Principal Investigators

  • Brian D. Foy, PhD · Colorado State University

  • Sunil Parikh, MD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-13
Primary Completion
2020-11-08
Completion
2024-08-01

Countries

  • Burkina Faso

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03967054 on ClinicalTrials.gov